

S-Table 1. Characteristics of patients with Control, IPF or OP

Variables	Control [#] (n=9)	IPF (n=18)	OP (n=8)	Control vs OP P value	IPF vs OP P value
Male, n (%)	3 (33.3)	15 (83.3)	3 (37.5)	0.87	0.02
Age (years)	56±4	61±8	55±12	0.96	0.20
Current smoker, n (%)	2 (22.2)	7 (38.9)	1 (12.5)	0.63	0.19
Smoking index	78 (0~400)	580 (0~2000)	31 (0~200)	0.45	0.02
Underlying diseases, n (%)					
Hypertension	3 (33.3)	6 (33.3)	2 (25)	0.73	0.69
Diabetes	3 (33.3)	5 (27.8)	3 (37.5)	0.87	0.64
Cardiovascular disease	N/A	2 (11.1)	N/A	N/A	0.35
Cerebrovascular disease	N/A	1 (5.6)	1 (12.5)	0.37	0.56
Vital signs at admission					
RR (breaths/min)	19 (17~20)	19 (17~22)	20 (18~25)	0.42	0.26
HR (beats/min)	89±7	85±9	81±11	0.18	0.38
SBP (mmHg)	134 (91~162)	134 (104~167)	131 (97~156)	0.84	0.70
DBP (mmHg)	86 (61~111)	87 (74~124)	82 (64~92)	0.55	0.28
Laboratory data at admission					
PH	7.43 (7.41~7.46)	7.43 (7.39~7.49)	7.45 (7.42~7.49)	0.20	0.20
PaCO ₂ (mmHg)	40.0 (35.4~42.2)	38.64 (29.6~47.2)	39.02 (34.1~42.8)	0.64	0.86
Lactate (mmol/L)	0.82 (0.80~1.10)	1.15 (0.70~1.6)	0.95 (0.80~1.40)	0.52	0.20
White blood cell(×10 ⁹ /L)	6.3 (3.7~8.3)	7.1 (4.0~10.9)	8.2 (5.2~10.3)	0.09	0.18
Neutrophil granulocyte (×10 ⁹ /L)	3.9 (2.1~5.4)	4.3 (1.8~8.1)	5.4 (3.3~7.9)	0.08	0.12
Lymphocyte (×10 ⁹ /L)	2.1 (1.4~3.2)	2.1 (1.4~3.1)	2.1 (1.3~4.1)	0.96	0.92
Haemoglobin (g/L)	141±18	128±46	134±14	0.46	0.72
Platelet (×10 ⁹ /L)	265±94	211±100	270±93	0.93	0.18
C-reactive protein (mg/L)	4.4 (1.2~8.0)	6.0 (1.0~23.1)	5.9 (0.5~10.0)	0.36	0.97
Procalcitonin (ng/ml)	0.05 (0.05~0.05)	0.05 (0.05~0.05)	0.05 (0.05~0.05)	1.00	1.00
ESR (mm/h)	25 (5~70)	27 (2~120)	43 (10~100)	0.31	0.26
ALT (U/L)	22.1 (11.8~32.7)	29.9 (7.4~135.4)	15.4 (8.8~37.0)	0.17	0.23
AST (U/L)	24.9 (17.9~42.2)	26.3 (11.8~87.6)	19.2 (10.8~31.1)	0.21	0.30
Creatinine (umol/L)	62.2±17.0	70.5±15.5	55.1±8.6	0.35	0.02

D-Dimer (mg/L)	0.12 (0.01~0.61)	0.21 (0.08~0.42)	0.21 (0.02~0.56)	0.42	1.00
Pulmonary function test					
TLC (%)	N/A	79.1 (57.2~92.0)	71.5 (54.0~90.0)	N/A	0.11
FVC (%)	N/A	82.4±9.3	75.7±12.9	N/A	0.22
DLCO (%)	N/A	71.7±11.5	68.6±18.6	N/A	0.67
Rcn3 level in balf (ng/ml)	6.27 (1.45~12.96)	5.79 (2.18~9.55)	14.85 (10.00~17.79)	<0.001	<0.001

IPF, idiopathic pulmonary fibrosis; OP, organizing pneumonia; RR, respiratory rate; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; PaCO₂, arterial carbon dioxide tension; ESR, erythrocyte sedimentation rate; AST, aspartate transaminase; ALT, alanine aminotransferase; TLC, total lung capacity; FVC, forced vital capacity; DLCO, lung diffusing capacity for carbon monoxide. # Control: subjects undergoing bronchoscopy with BAL for evaluation of incidentally detected pulmonary nodules, with normal HRCT and lung function; interstitial lung disease and active infection were excluded.

S-Table 2. Primer table of quantitative polymerase chain reaction

Primers for human genes	
hGAPDH-F	GAAGGTGAAGGTCGGAGTC
hGAPDH-R	GAAGATGGTGATGGGATTTC
hColla1 F	GAGGGCCAAGACGAAGACATC
hColla1 R	CAGATCACGTCATCGCACAAAC
hColla2 F	GTTGCTGCTTGCAGTAACCTT
hColla2 R	AGGGCCAAGTCCAACTCCTT
h α -SMA F	GGCATTACGAGACCACCTAC
h α -SMA R	CGACATGACGTTGTTGGCATAAC
hPCNA F	CCTGCTGGGATATTAGCTCCA
hPCNA R	CAGCGGTAGGTGTCGAAGC
hCTGF F	ACAAGGGCCTCTTCTGTGACTT
hCTGF R	GGTACACCGTACCACCGAAGAT
hTGF β 1 F	GACAACGTCAGGTTCTGGCTCA
hTGF β 1 R	CCGCCACTTTCCTCTCCAAACT
hTGF β 2 F	CTGCCCATCCACTGAGACATA
hTGF β 2 R	AGCTTGGGGTCATGGCAAAC
hTGF β 1 F	CTACTGCTTCAGCTCCACAG
hTGF β 1 R	GCACTTGCAGGAGCGCAC
Primers for mouse genes	
IL1 β F	GCAACTGTTCTCTGAAGTCAACT
IL1 β R	ATCTTTTGGGGTCCGTCAACT
TNF α F	CAGGCGGTGCCTATGTCTC
TNF α R	CGATCACCCCGAAGTTCAGTAG
IL-6 F	CTGCAAGAGACTTCCATCCAG
IL-6 R	AGTGGTATAGACAGGTCTGTTGG
Colla1 F	CCAAGAAGACATCCCTGAAGTCA
Colla1 R	TGCACGTCATCGCACACA
Colla2 F	AGCTTTGTGGATACGCGGACT
Colla2 R	TCGTAAGTATCCCGATTGCA
α -SMA F	CGGGAGAAAATGACCCAGATT
α -SMA R	GGACAGCACAGCCTGAATAGC
TGF β 1 F	GCCCTGGATACCAACTATTGC
TGF β 1 R	AAGTTGGCATGGTAGCCCTT
RPL19 F	ATGAGTATGCTCAGGCTACAGA
RPL19 R	GCATTGGCGATTTCATTGGTC